NASA Technical Reports Server (NASA) · 1989 · 10 citations · 0 references
Life SciencesCancer BiologyImmunologyClinical ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCombination ImmunotherapyImmune ModulationImmunostimulatory TherapyImmunotherapy For Solid TumorsCombination Immunotherapy EffectsPrecision ImmunotherapyTurbulent Wake StructureVortex Dynamics Of WakesWake FlowWake Formation
<i>EGFR-, ALK-, HER2-, RET-</i>, and <i>ROS1</i>-altered NSCLC patients have poor reactivity to monoimmunotherapy but the efficacy of immune-based combined therapy is significantly improved. <i>KRAS</i> G12C mutation, <i>BRAF</i> non-V600E mutation, and <i>MET</i> amplification have better responses to immunotherapy, and more prospective studies are needed for further research.